Sensory evaluation using mitiglinide / voglibose orally disintegrating tablets (OD tablets) and study of efficacy and safety

Sensory evaluation using mitiglinide / voglibose orally disintegrating tablets (OD tablets) and study of efficacy and safety - Sensory evaluation using mitiglinide / voglibose orally disintegrating tablets (OD tablets) and study of efficacy and safety

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039068

Enrollment

Registered

2020-01-07

Start date

2020-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatient who is going to Hotaruno Central Internal Medicine Patients treated with mitiglinide / voglibose combination tablets 3 times a day for more than 2 months before changing to mitiglinide / voglibose combination OD tablets Patients who wished to change treatment to take mitiglinide / voglibose OD tablets 3 times a day, before explaining about this clinical study Patients who can answer questionnaires themselves Patients with written consent Patients over 20 years old at the time of obtaining informed consent

Exclusion criteria

Exclusion criteria: Patients who are judged inappropriate by the research doctor for this study

Design outcomes

Primary

Measure	Time frame
Sensory evaluation questionnaires	—

Secondary

Measure	Time frame
HbA1c Adverse events/Adverse reactions (hypoglycemic symptoms, etc.)	—

Countries

Japan

Contacts

Public ContactKaori Iwatake

Satt Co., Ltd. Clinical Study Group

kaori.iwatake@sa-tt.co.jp03-5312-5026

Outcome results